@article{5d0b529aa4f84b1c80a887f9db29366c,
title = "A STING operation to expose KRAS and STK11 co-mutated lung cancers",
abstract = "KRAS and STK11 (LKB1) co-mutated (KL) tumors define an immunologically cold and anti-PD-(L)1-refractory non-small-cell lung cancer (NSCLC) subset. In this issue of Cancer Cell, Kitajima et al. outline a strategy to unleash innate immunity in KL tumors by utilizing epigenetic de-repression of STING and pulsed inhibition of spindle assembly checkpoint kinase MPS1.",
author = "Ferdinandos Skoulidis and Heymach, {John V.} and Tina Cascone",
note = "Funding Information: F.S. reports consulting fees and advisory roles from Amgen Inc. , AstraZeneca Pharmaceuticals, Novartis , BeiGene, Tango Therapeutics, Calithera Biosciences, Navire Pharma, Medscape LLC, Intellisphere LLC, Guardant Health, and BergenBio; speaker fees from BMS , RV Mais Promocao Eventos LTDS, the Visiting Speakers Program in Oncology at McGill University and the Universit{\'e} de Montr{\'e}al, AIM Group International, and ESMO; fees for travel, food, and beverage from Tango Therapeutics, AstraZeneca Pharmaceuticals, Amgen Inc. , Guardant Health, and Dava Oncology; stock or stock options in BioNTech SE and Moderna Inc.; research grants (to institution) from Amgen Inc., Mirati Therapeutics, Boehringer Ingelheim , Merck & Co, and Novartis; Study Chair funds (to institution) from Pfizer; and research grants (spouse, to institution) from Almmune. J.V.H. reports advisory roles and consulting fees from AstraZeneca , EMD Serono , Boehringer-Ingelheim, Catalyst, Genentech , GlaxoSmithKline , Hengrui Therapeutics, Eli Lilly , Spectrum , Sanofi , Takeda , Mirati Therapeutics, BMS , BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, RefleXion, and Chugai Pharmaceuticals; institutional research funding from AstraZeneca , Boehringer-Ingelheim, Spectrum , and Takeda ; and royalties and licensing fees from Spectrum . T.C. reports speaker fees and honoraria from the Society for Immunotherapy of Cancer , Bristol Myers Squibb , Roche , Medscape, and PeerView; travel, food, and beverage expenses from Dava Oncology and Bristol Myers Squibb; advisory roles and/or consulting fees from MedImmune / AstraZeneca , Bristol Myers Squibb , EMD Serono , Merck & Co., Genentech , Arrowhead Pharmaceuticals, and Regeneron; and institutional research funding from MedImmune / AstraZeneca , Bristol Myers Squibb , Boehringer-Ingelheim, and EMD Serono . Funding Information: The authors thank Mr. David Aten, MA, CMI, from Strategic Communications - Creative Communications at the University of Texas MD Anderson Cancer Center for the creation of the original figure accompanying this preview. F.S. reports consulting fees and advisory roles from Amgen Inc., AstraZeneca Pharmaceuticals, Novartis, BeiGene, Tango Therapeutics, Calithera Biosciences, Navire Pharma, Medscape LLC, Intellisphere LLC, Guardant Health, and BergenBio; speaker fees from BMS, RV Mais Promocao Eventos LTDS, the Visiting Speakers Program in Oncology at McGill University and the Universit{\'e} de Montr{\'e}al, AIM Group International, and ESMO; fees for travel, food, and beverage from Tango Therapeutics, AstraZeneca Pharmaceuticals, Amgen Inc., Guardant Health, and Dava Oncology; stock or stock options in BioNTech SE and Moderna Inc.; research grants (to institution) from Amgen Inc. Mirati Therapeutics, Boehringer Ingelheim, Merck & Co, and Novartis; Study Chair funds (to institution) from Pfizer; and research grants (spouse, to institution) from Almmune. J.V.H. reports advisory roles and consulting fees from AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, RefleXion, and Chugai Pharmaceuticals; institutional research funding from AstraZeneca, Boehringer-Ingelheim, Spectrum, and Takeda; and royalties and licensing fees from Spectrum. T.C. reports speaker fees and honoraria from the Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; travel, food, and beverage expenses from Dava Oncology and Bristol Myers Squibb; advisory roles and/or consulting fees from MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co. Genentech, Arrowhead Pharmaceuticals, and Regeneron; and institutional research funding from MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer-Ingelheim, and EMD Serono. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = oct,
day = "10",
doi = "10.1016/j.ccell.2022.09.010",
language = "English (US)",
volume = "40",
pages = "1073--1076",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "10",
}